NCT02996019 - A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI) | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

December 7, 2016

Primary Completion Date

April 9, 2018

Study Completion Date

April 9, 2018

Conditions

Healthy Volunteers

Interventions

DRUG

Etrolizumab

Etrolizumab will be administered at a dose of 105 milligrams (mg).

DEVICE

Auto-Injector (AI)

The pre-filled AI will be used to administer etrolizumab.

DEVICE

Prefilled Syringe With Needle Safety Device (PFS-NSD)

The PFS-NSD will be used to administer etrolizumab.

Trial Locations (4)

Covance Research Unit - Daytona, Daytona Beach

Covance Clinical Research Unit Inc.; Covance Gfi Research, Evansville

Covance Clinical Research Unit, Inc, Madison

Covance Research Unit - Dallas, Dallas